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Anti-inflammatory and immunomodulatory effects of statins. that weaken the fibrous cap making lesions vulnerable
3-Hydroxy-3-methyl-gutaryl coenzyme A (HMG-CoA) reduc- to rupture by the action of the hemodynamic forces [2–4].
tase inhibitors or statins constitute the most powerful class of Fibrous cap rupture allows the blood to contact with thelipid-lowering drugs. Clinical trials have demonstrated a
atheromatous gruel, which is highly procoagulant [5, 6],marked reduction in cardiovascular mortality in patients treated
triggering thrombosis. According to this process, it haswith statins. However, the benefits observed with statin therapy
appear to be related, at least in part, with their cholesterol- been observed that atherosclerotic plaques responsible for
lowering independent effects. Extensive research carried out an acute coronary event are infiltrated by macrophages,
mainly in the last decade suggests that the clinical benefits of T lymphocytes and activated VSMC [7] more frequentlythese drugs could be related to an improvement in endothelial
than those that are stable [8]. Moreover, expression ofdysfunction, a reduction in blood thrombogenicity, anti-inflam-
MMPs has been found in human atherosclerotic plaquesmatory properties, and, recently, immunomodulatory actions.
In this sense, statins decrease T cell activation, the recruitment located mainly near macrophage infiltrates and in the
of monocytes and T cells into the arterial wall, and enhance shoulder region [4, 9, 10]. This explains in part why this
the stability of atherosclerotic lesions. Many of these effects region, where the lesions join the normal arterial wall,are related with the inhibition of isoprenoid synthesis, which
is the most vulnerable to rupture. Accordingly, we andserve as a lipid attachment for a variety of proteins implicated in
others have observed that human specimens of carotidintracellular signaling. In fact, small G proteins, whose proper
membrane localization and function are dependent on isopren- endarterectomy display an increase of macrophage infil-
ylation, may play an important role in the lipid-lowering inde- trate and a decrease in VSMC in this region as compared
pendent effects of HMG-CoA reductase inhibitors. This article with other zones of the plaque [abstract; Martı´n-Venturasummarizes the anti-inflammatory and immunomodulatory ef-
et al, Circulation 102(Suppl II):319, 2000] [11].fects of statins and their participation in the different steps of
The concept of atherosclerosis as an inflammatory dis-atherosclerotic lesion formation.
order has led to an exploration of new avenues in the
pathogenesis of this disease. In this sense, the levels of
Atherosclerosis is currently described as an inflamma- several inflammatory molecules in circulating blood are
tory disease [1], given that the main components of chronic increased more frequently in subjects at risk of devel-
inflammation such as cell recruitment, sclerosis, cell pro- oping an acute coronary event [12–16]. This reflects a
liferation and neovascularization are present in this pro- relationship between the events that are taking place in
cess. Moreover, recruitment of inflammatory cells is in- the blood and into the vessel wall. This is not surprising
volved in plaque rupture and subsequent thrombosis. since, as explained, inflammatory cells are circulating in
Atherosclerotic lesions are formed by a lipid-rich nucleus the blood before entering the atherosclerotic lesion. In
covered by a fibrous cap. This cap confers the lesions fact, using a rabbit model of atherosclerosis, we demon-
resistance to rupture, and consists of collagen and other strated a significant correlation between the inflamma-
extracellular matrix proteins, synthetized by vascular tory activity of circulating monocytes and that of the
smooth muscle cells (VSMC) [2–3]. Inflammatory cells, cells present in the atherosclerotic plaques [17]. To-
mainly macrophages, release metalloproteinases (MMP) gether, these data suggest that the grade of activity of
inflammatory cells is determined before they enter the
arterial wall. Another advance derived from the inflam-
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matory concept of atherosclerosis is related to therapeu-itors, lesion, G proteins, blood thrombogenecity, cardiovascular mor-
tality, lipid lowering. tics. Several drugs efficient in the treatment of atheroscle-
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Table 1. Immunomodulatory and anti-inflammatory effects of [33]. Furthermore, lovastatin decreases CD11b-depen-
HMG-CoA reductase inhibitors
dent adhesion of monocytes stimulated or not with
Anti-inflammatory effects Immunomodulatory effects monocyte chemoattractant protein-1 (MCP-1) [34], and
↓ Adhesion molecules ↓ Proliferation of lymphoid cells fluvastatin reduces the leukocyte-adherence responses
↓ Chemoattractant proteins ↓ Natural killer activity to platelet-activating factor and to leukotriene B4 in↓ Proinflammatory transcription ↓ Major histocompatibility
hypercholesterolemic rats [35]. Also, statins blocked thefactors class II antigens
↓ Proinflammatory enzymes ↓ Organ rejection adhesion of lymphocytes mediated by leukocyte function
↓ Inflammatory serum markers antigen-1 (LFA-1), a 2 integrin expressed on leukocyte
surface that binds to ICAM-1 [36]. According to these
data, Seljeflot et al demonstrated recently that atorva-
statin and simvastatin reduce plasma levels of ICAM-1,
has been suggested to have a protective role in coronary VCAM-1, E-selectin and P-selectin in in patients with
artery disease, has anti-inflammatory properties [21]. coronary artery disease [37].
Recruitment of mononuclear cells
ANTI-INFLAMMATORY EFFECTS OF STATINS
After adhesion, monocytes enter the arterial wall in
Since the demonstration that hydroxy-methyl-glutaryl a process driven by chemoattractant molecules. HMG-
coenzyme A (HMG-CoA) reductase inhibitors (statins) CoA reductase inhibitors have been shown to exten-
reduce mortality and the incidence of coronary events sively interfere with this step. In a rabbit model of athero-
[22], great effort has been made to elucidate the underly- sclerosis we demonstrated that atorvastatin decreases
ing mechanisms of these effects. Angiographic studies re- the expression of chemoattractant molecules MCP-1 and
vealed that the reduction in lesion progression achieved interleukin-8 (IL-8) [20, 38]. As a consequence, there
by these drugs was too mild to fully explain them [23]. was a reduction in macrophage infiltration and MMP-3
Also, the clinical benefits appear after too short an inter- expression. The mechanism of the reduction of MCP-1
val of treatment time to see any significant effect on plaque and IL-8 expression seemed to be due to a decrease in
progression [24]. Extensive research carried out mainly in the activation of nuclear factor-B (NF-B; Fig. 1). This
the last decade suggests that, instead of an improvement redox-sensitive transcription factor is involved in the trans-
in endothelial function [25], the clinical benefit of these mission of various signals from the cytoplasm to the nu-
drugs could be related to a reduction in blood thrombo- cleus of numerous cell types [39]. It is found in the cytosol
genicity [26] and to anti-inflammatory properties. More- as a trimer consisting of p50 and p65 subunits bound to
over, it has been shown that these actions in part could its inhibitor IB. The release of IB from the trimer
be independent of the lipid-lowering effects of statins. results in the migration of the p50/p65 heterodimer to the
This review focuses on the anti-inflammatory and immu- nucleus and subsequent DNA binding [40]. This process
nomodulatory actions of statins (Table 1). activates genes involved in the immune, inflammatory
or acute phase response, such as adhesion molecules, che-
Endothelial dysfunction and adhesion moattractant cytokines like MCP-1 and IL-8, proinflam-
One of the early stages in atherogenesis is the adhesion matory enzymes such as cyclooxygenase-2 (COX-2), and
of monocytes to the endothelium, which acquires an procoagulant proteins as tissue factor (TF) and plasmin-
activated phenotype due to various stimuli. This activa- ogen activator inhibitor-1 (PAI-1) [41, 42]. Data strongly
tion is believed to be related to a decrease in nitric oxide suggest that NF-B could be involved in the pathogenesis
(NO) availability, which may be secondary to different of atherosclerosis [43], since it participates in dysregula-
cardiovascular risk factors (hypertension, dislipidemia, tion of VSMC in human atherosclerosis [44] and is pres-
diabetes, and so forth) [25, 27–31]. This dysfunctional ent in the nuclei of macrophages and endothelial cells
endothelium will express different adhesion molecules of human atherosclerotic lesions [45]. Moreover, Wilson
such as intercellular adhesion molecule-1 (ICAM-1), vas- et al have shown that it is present more markedly in
cular adhesion molecule-1 (VCAM-1) and E-selectin, cells from human atherosclerotic lesions that have been
which are essential for the first steps of monocyte recruit- responsible for an acute coronary syndrome [46], sup-
ment: rolling and adhesion to the endothelium. porting the hypothesis of a link between inflammation
In addition to the above-mentioned benefits of statins and plaque instability.
in endothelial dysfunction, different components of this Cyclooxygenase-2 expression was reduced also by
family have been shown to regulate inflammatory cell statin treatment [38]. This isoform of COX was first
adhesion. Fluvastatin treatment inhibits the expression related to inflammation in rheumatic diseases and en-
of ICAM-1 on human monocytes [32] and cerivastatin hances the production of the chemoattractant prosta-
prevents lipopolysaccharide (LPS)-induced ICAM-1 ex- glandin E2 [47]. Later, it was confirmed that it behaves
similarly in the arterial wall, as it appears in atherosclero-pression in endothelial cells via inhibition of Rho activity
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Fig. 1. Effect of atorvastatin on NF-B activation in atherosclerotic lesions of experimental rabbits. NF-B was determined by Southwestern
histochemistry in untreated (A), atorvastatin treated (B), and control (C ) animals. Magnification400. Adapted from reference [20], with permission
from the American College of Cardiology Foundation Journal of the American College of Cardiology, 1998. (D) Schematic representation of
NF-B activation. NF-B activation leads to coordinated expression of different genes that encode proteins such as cytokines, chemokines, adhesion
molecules and enzymes, involved in the initiation and perpetuation of the inflammatory response.
sis, but is absent in the healthy vessel [48]. In addition, -9 and tissue factor in the same model, and decreases
macrophage proliferation and the proteolytic activityCOX-2 has been demonstrated to colocalize with prosta-
glandin E2 (PGE2) synthase, with macrophages and due to MMP-9 in human macrophages in vitro [51]. The
same group demonstrated that pravastatin and fluva-MMP-9 in human carotid atherosclerosis [49]. Of inter-
est, COX-2 expression was more intense in the lesions statin reduced MMP-3 and MMP-9 expression in the
absence of modifications of the macrophage infiltrate,of patients who had suffered an ipsilateral stroke [49].
These data showing the blockade of cell recruitment suggesting a reduction in their expression [52]. Accord-
ingly, Bellosta et al also demonstrated that statins inhibitinto the arterial wall by statins are reinforced by studies
from other groups. Shiomi and Ito reported that ceriva- the expression of MMP-9 by macrophages [53]. Then,
HMG-CoA reductase inhibitors do not only decreasestatin treatment retarded the enlargement of plaque size
and reduced macrophage accumulation in Watanabe her- the macrophage infiltrate in the vascular wall, but also
reduce the ability of these inflammatory cells to produceitable hyperlipidemic rabbits [50]. Furthermore, Aikawa
et al demonstrated that cerivastatin reduces the macro- MMPs.
As seen, most of the evidence for the ability of statinsphage infiltrate and the expression of MMP-1, -3 and
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to reduce the inflammatory infiltrate in the arterial wall These studies indicate that statins are effective in decreas-
ing not only vascular, but also systemic inflammation.comes from animal experimentation. This is logical, since
animals can be randomized to statin or no treatment
during the study period and afterwards be sacrificed in IMMUNOMODULATORY EFFECTS OF STATINS
order to analyze the composition of atherosclerotic le-
The triggers of the inflammatory response observedsions. However, Crisby et al have demonstrated recently
in atherosclerosis have not been completely elucidated.that there is an experimental design allowing the investi-
It has been suggested that autoantigens expressed in thegation of the effects of statins in human atherosclerosis.
atherosclerotic plaque may induce an immune response.They studied patients with symptomatic carotid stenosis
One of these possible antigens, heat-shock protein 70who were scheduled for a carotid endarterectomy [54].
has been demonstrated to be present around sites ofThree months before the operation, the patients were
necrosis and lipid accumulation, colocalizing with macro-randomized to pravastatin versus no lipid-lowering ther-
phages, in human and rabbit atheroma [72]. Other pro-apy and, at surgery, endarterectomy specimens were col-
posed antigens, such as low-density lipoprotein (LDL)lected and analyzed. Patients receiving pravastatin had
and non-LDL oxidative epitopes, are also more fre-less macrophage and T cell infiltration, reduced MMP-2
quently present in atherosclerotic than in normal human
expression as well as a higher immunoreactivity for tissue
arteries [73]. In fact, T cells derived from human athero-
inhibitor of MMP-1. Probably as a result of the lower sclerosis respond to oxLDL by proliferation and cytokine
collagenolytic activity, the collagen content was higher in secretion [74]. It also has been speculated that infectious
patients on pravastatin therapy, suggesting a stabilizing agents could stimulate immunity in this disorder [75, 76].
effect of atherosclerotic lesions. The presence of activated T lymphocytes in the periph-
eral blood and coronary plaques of patients with acuteInflammatory serum markers and statins
coronary syndromes supports the hypothesis of an im-
Different markers of inflammation have been studied mune response in the pathogenesis of coronary athero-
to analyze the effect of statins on inflammatory states. In sclerosis [7, 76–78]. According to this hypothesis, there
particular, high-sensitivity C-reactive protein (hs-CRP) is an increase of CD4 and CD3/DR T cells and
reflects low-grade systemic inflammation [55]. Human of IL-2 and IgM in patients with unstable angina [75].
studies have demonstrated that statins are able to reduce Furthermore, in this condition, monocytes present nu-
CRP serum levels in hyperlipidemic patients [14, 56–59], clear translocation of STAT-1 complexes and up-regula-
including those who are on hemodialysis [60]. The impor- tion of CD64 and IP-10 genes, which are known to be
tance of this effect is related to the demonstration that inducible by interferon- (IFN-) [79]. This points to a
the increment of CRP levels has a predictive value of possible monocytic activation via IFN- produced by
the possibility of an acute coronary event [13–16, 61]. stimulated T lymphocytes. In accordance with this hy-
Accordingly, these drugs are especially effective in re- pothesis, it has been observed that monocytes need incu-
ducing the incidence of coronary events in the population bation and contact with lymphocytes to express procoag-
with high levels of CRP [14, 62]. ulant activity [80].
Different adhesion molecules such as VCAM-1, ICAM-1 Different effects of statins on lymphoid cell function
and E-selectin also have been proposed as markers of have been shown. For example, suppression of prolifera-
cardiovascular risk [63–65]. Statin therapy decreases tion or natural killer cell activity by compactin [81], lova-
E-selectin levels and the effects on other adhesion mole- statin [82] and simvastatin [83] has been reported in
cule levels have been discordant [37, 66]. in vitro experiments. Lovastatin, by binding to LFA-1,
Other inflammatory molecules are affected by statins. exerts an immunomodulatory effect, because this integ-
Serum MMP-9 levels, which have been found to increase rin does not only play a role in leukocyte adhesion, but
during acute coronary syndromes [67], are decreased by does also work as a T cell co-stimulator [36]. Kwak et
pravastatin in clinically healthy men, reflecting the reduc- al demonstrated that different statins inhibit the expres-
tion of nonsymptomatic chronic arterial inflammation sion of major histocompatibility class II (MHC II) anti-
[68]. Hypercholesterolemic individuals treated with pra- gens by primary human macrophages and endothelial
vastatin and simvastatin show a reduction in the levels of cells in response to IFN- [84]. This effect resulted from
the proinflammatory cytokines tumor necrosis factor- the reduced activation of the inducible promoter IV on
(TNF-) [69, 70] and IL-1 [70]. Finally, the activity of the transactivator CIITA [85] and was limited to cells
the transcription factor NF-B in circulating leukocytes that express MHC II only in response to IFN- stimula-
is enhanced in patients with unstable angina and in healthy tion [84]. In contrast, professional antigen-presenting
volunteers after a fat-enriched meal [21, 71]. Treatment cells constitutively expressing MHC II, such as B lym-
with simvastatin reduces this activity in mononuclear cir- phocytes and dendritic cells, were not inhibited, and nei-
ther was MHC I expression.culating cells in the rabbit model of atherosclerosis [17].
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Major histocompatibility class II antigen is required MECHANISMS OF ANTI-INFLAMMATORY
EFFECTS OF STATINSfor antigen presentation and T-cell activation through
the T cell receptor. This T-cell receptor may trigger prolif- Actions related to lipid lowering
eration of other T cells, their differentiation into two dif- Statins were developed as lipid-lowering drugs. HMG-
ferent effector cell populations (T helper 1 and 2 cells; CoA reductase inhibition leads to a decrease in intracel-
Th1 and Th2) and cytokine release. In this sense, Th1 lular cholesterol synthesis. To compensate for the intra-
cells secrete proinflammatory cytokines such as IFN- cellular diminution in cholesterol levels, some cells, mainly
and TNF-. In contrast, Th2 cells produce anti-inflam- hepatocytes, expose external receptors that promote up-
matory cytokines interleukin-4 (IL-4), IL-10, IL-13 and take and clearance of cholesterol from the blood. Given
transforming growth factor- (TGF-). It has been sug- the relationship between hyperlipidemia and atheroscle-
gested that the ability of statins to down-regulate the rosis, it seems wise to consider that their hypolipidemic
expression of MHC II may lead to decreased Th1 activa- effect is responsible for a part of their biological actions,
tion in vivo and inhibition of the pro-inflammatory cyto- including the anti-inflammatory effects.
kines release. Accordingly, statins reduce T cell prolifer- In human studies, it has been observed that hypercho-
ation and IL-2 release [84]. However, these drugs may lesterolemia up-regulates the pro-inflammatory receptor
induce opposite effects via a similar impact on Th2 prolif- CD40 and its ligand CD40L [95]. This system is expressed
eration and effector function or shift toward a Th1 im- in the cells of the atherosclerotic lesions where it medi-
mune response [86]. ates the production of cytokines, MMPs and tissue factor
Clinical research has been carried out to examine the [96]. Moreover, levels of soluble CD40L are increased
immunomodulatory effect of statins, and the results have in acute coronary syndromes [97, 98] and predict their
incidence in healthy women [99]. In animal models, hy-been discordant. Muldom et al did not find any effect
perlipidemia also enhances NF-B activation, the expres-of six months of lovastatin on the number and function
sion of adhesion and chemoattractant molecules, and fa-of circulating immune cells [87]. However, Kobashigawa
vors macrophage infiltrate into the vessel wall [20, 35,et al have demonstrated that pravastatin reduces the
100]. In vitro studies have confirmed that lipids are re-cytotoxicity of natural killer cells and the incidence of
lated to inflammatory activation of the cells from thecoronary vasculopathy in patients that have undergone
vessel wall. It has been demonstrated that oxidized LDLcardiac transplantation [88]. Moreover, although it had
increases NF-B activation and MMP-9 expression inno effect on the incidence of mild and moderate episodes
culture human monocyte-derived macrophages [101]. Also,of cardiac rejection, pravastatin decreased the incidence
CD40L expression and IFN- production are enhancedof rejection with hemodynamic impairment and reduced
by lysophosphatidylcholine in human CD4 T cells [102].mortality [88]. In a similar population, Wenke et al
Probably the best data confirming that a part of theshowed that simvastatin significantly increased survival
anti-inflammatory effects of statins are related to lipidand reduced the incidence of coronary artery disease
lowering arise from animal experimentation. Aikawaand intimal thickness at four years of follow-up, although
et al demonstrated that reducing lipid levels only byit did not affect the incidence of cardiac rejection [89].
dietary modification, in the rabbit model of atherosclero-
Data on kidney-transplanted patients are, for the mo-
sis, decreases the expression of CD40 and CD40L colo-
ment, less promising. Although a small study with 48 calizing with a reduction of tissue factor immunoreactiv-
patients showed a decrease in acute rejection [90], three ity [103]. Also, a diminution of macrophage infiltrate,
larger randomized trials involving a total of 570 patients MMP-1 expression and proteolytic activity was observed
failed to confirm these data [91–93]. However, in these in the same model [104]. Together these data underline
studies the patients were followed for only three months, the fact that lipid lowering is one of mechanisms by
a short period when compared with the one to four years which statins decrease inflammation in atherosclerosis.
reported in the cardiac transplant studies [88, 89]. Thus,
it would be interesting to know the effects of prolonged Lipid-independent mechanisms
statin administration and a longer follow-up period in A large body of data has accumulated in the last years
this population. The ongoing ALERT trial may shed suggesting that some effects of statins, for example, their
some light on this issue. In this study, 2100 patients with actions on endothelial dysfunction and the anti-inflamma-
functioning renal allografts and mild-to-moderate hyper- tory effects, could be independent of their lipid-lowering
cholesterolemia are being randomized to fluvastatin or ability. This was supported by clinical studies such as the
placebo and will be followed up to six years. Although WOSCOPS study, where evidence showed that patients
the primary objective of this trial is the incidence of major on pravastatin had fewer coronary events than those on
adverse cardiac events, it will also provide information placebo who had similar LDL levels [105]. Moreover, in
the same study, plasma lipids at baseline did not influenceon renal function and all causes of mortality [94].
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the relative risk reduction achieved by pravastatin. In tachment of an isoprenoid residue to these proteins is
necessary for their anchorage to the cell membranes andaddition, the fall in LDL found in the pravastatin group
did not correlate with the risk reduction of coronary full functionality. Statins inhibit Ras and Rho isoprenyla-
tion leading to the accumulation of their inactive formsheart disease.
Evidence pointing to a direct anti-inflammatory action in the cytoplasm [112]. These proteins are implicated in
different functions in the cells such as gene expression,of HMG-CoA reductase inhibitors comes from both clin-
ical and experimental studies. The reduction of CRP organization of the actin cytoskeleton, membrane traf-
ficking, programmed cell death, proliferation and trans-serum levels achieved by different statins is not related
to the decrease in lipid levels [14, 57–60]. formation [113, 114]. Inhibition of Rho and its down-
stream target, Rho kinase, is a possible mechanismResearch in animal models of atherosclerosis strongly
supports the idea of a direct anti-inflammatory effect of mediating some of the pleiotropic effects of HMG-CoA
reductase inhibitors on the vascular wall, since changesstatins. Williams et al showed a decrease in macrophage
infiltration in atherosclerotic monkeys after treatment in Rho can affect intracellular transport, membrane traf-
ficking, mRNA stability, and gene transcription [115].with pravastatin and diet manipulation to avoid changes
in serum lipid levels [106]. More recently, simvastatin Accordingly, we have seen, for example, that atorva-
statin directly reduces the expression of MCP-1 and IL-8has been found to reduce inflammation in a model of
carrageenan-induced footpad edema in mice [107]. Sim- as well as NF-B activation induced by angiotensin II
(Ang II) and TNF- in cultured monocytes and VSMCvastatin also has been found to reduce leukocyte rolling
and adherence in rats [108] and apolipoprotein E-defi- [116]. These effects have been related to the inhibition
of non-sterol compounds of the mevalonate pathway,cient mice [109], leukocyte transmigration in rats [108]
and the aorta cholesterol content in apolipoprotein such as FPP and GGPP, which restored the inhibition
of NF-B activity induced by atorvastatin. Moreover,E-deficient mice [107] in the absence of lipid change. In
a recent work from our group, atherosclerotic rabbits Manumicyn A, an isoprenylation inhibitor, abolishes
were randomized to simvastatin treatment and a hyper- NF-B activity induced by Ang II and TNF- [116].
lipidemic diet versus a normolipidemic diet. Given that Other transcription factors also seem to be regulated
the hyperlipidemic diet counterbalanced the effect of by statins. Treatment with different statins can modulate
simvastatin, the reduction of lipid levels in this group proinflammatory cytokines expression such as IL-1,
was less pronounced. However, NF-B activity in mono- IL-6, and COX-2 by up-regulating the peroxisome prolif-
nuclear cells and atherosclerotic lesions was reduced erator activated receptor- in endothelial cells [117]. Ac-
more markedly in the simvastatin group [17]. Similar tivator protein-1 (AP-1) activation is decreased by statin
results were obtained when macrophage infiltration and treatment in renal epithelial tubular cells [118]. In addi-
the expression of IL-8 and MMP-3 were analyzed. The tion, atorvastin and simvastatin increase the activation
observation that simvastatin had a greater anti-inflam- of the octamer transcription factor Oct-1 in mononuclear
matory action than diet modification in spite of less lipid cells, which represses the transcription of proinflamma-
lowering, suggests that a part of these effects may be tory genes such as IL-8, CD11c/CD18, VCAM1 and
due to mechanisms independent of lipid modification. PECAM-1 [119].
Despite the information obtained in vivo, the most com- Finally, it must be noted that HMG-CoA reductase
prehensive information about the mechanism of the direct inhibition is not the only possible mechanism through
actions of statins results from in vitro experiments. In which statins exert their effects. The above-mentioned
these studies, the effect of HMG-CoA reductase inhibi- inhibitory action of lovastatin on LFA-1 is unrelated to
tion on the cell types that form the atherosclerotic lesions this pathway [36]. This opens the possibility of devel-
was tested (Fig. 2). Given that the cells were isolated oping new statins with selectively potentiated immuno-
from the whole organism, the possibility of a decrease suppressive effects.
in extracellular lipids by the action of these drugs on the
liver disappeared, and it was possible to observe solely
OTHER EFFECTS OF STATINS ON THEtheir action on the studied cells. It was found that the
VASCULAR WALL RELATED WITHlipid-independent effects of these agents are related to
SMALL G PROTEINSthe inhibition of other isoprenoid intermediates of the cho-
The accumulation of VSMC in the neointima is an-lesterol biosynthetic pathway, such as farnesylpyrophos-
other feature of atherosclerosis and a consequence ofphate (FPP) and geranylgeranylpyrophosphate (GGPP)
their migration from the media and their proliferation[110]. FPP and GGPP are used for the post-translational
within the lesion [1]. Different studies have demonstratedmodification of several important cell proteins including
that treatment with statins inhibits proliferation of VSMCnuclear lamins, Heme-a, the  subunit of heterotrimeric
by arresting the cell cycle transition between the G1 to SG proteins, and small G proteins such as Ras and Ras-
like proteins (Rac, Rab and Rho; Fig. 2) [111]. The at- phase. The inhibition of VSMC proliferation was corre-
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Fig. 2. Small G proteins and vascular wall. Inhibition of HMG-CoA reductase by statins decreases isoprenylation of small G proteins such as
Ras, Rac and Rho. This effect leads to alteration of different functions in the cell.
lated with increases in the level of cyclin-dependent ki- increased fibrinolytic capacity, which is related to the inhi-
bition of PAI-1 expression from VSMC and endothelialnase inhibitor p27Kip1 and is related with the inhibition
of RhoA isoprenylation [120]. Antiproliferative effects cells [126]. Ang II plays crucial roles in the pathogenesis
of cardiovascular diseases, and statins down-regulateof statins in animal models without significant changes
in serum cholesterol concentrations also have been re- Ang II type 1 receptor in VSMC, an effect related again
with the inhibition of RhoA isoprenylation (Fig. 3) [127].ported [121, 122]. In addition, serum of patients treated
with statins decreases proliferation of VSMC in vitro [123].
Statins and postangioplasty restenosisThe accumulation of VSMC in the early step of athero-
sclerosis is the result of the migration from the media, One of the most important challenges in the treatment
of coronary artery disease is postangioplasty restenosis.proliferation and eventual death, including programmed
cell death. In this sense, we have demonstrated that lipo- This process is not identical to the evolution of spontane-
ous atherosclerosis, and is due to both intima thickeningphilic statins induced apoptosis of VSMC in culture and
this effect is related with the interference of protein with VSMC proliferation, and arterial wall remodeling.
In the last years, the use of stents has reduced the inci-isoprenylation [124]. These experiments used higher con-
centrations than those used in clinical practice, but it is dence of restenosis by controlling arterial remodeling
[128, 129], and stents are now implanted electively afterpossible that relatively low, but sustained plasma levels
of statins could exert a similar effect to that seen in vitro angioplasty in most cases.
Despite the antiproliferative effect of statins, severalwith higher concentrations. In this regard, Buemi et al
have demonstrated that there is an increment of apopto- studies have evidenced that these drugs fail to prevent
restenosis after balloon angioplasty [130–133]. However,sis in cultured VSMC following the addition of the serum
of fluvastatin-treated patients [125]. in a subset of patients treated with stent, statins seem
to be beneficial. Walter et al have evidenced recently thatFurthermore, different reports have demonstrated an-
other pleiotropic effect of statins related to the inhibition these drugs reduce the incidence of post-stent restenosis
specifically in those patients whose serum C reactiveof small G proteins isoprenylation. Statins may alter the
local fibrinolytic balance within the vessel wall toward protein levels are above 0.6 mg/dL [134]. These data
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Fig. 3. Pleiotropic effects of HMG-CoA reductase inhibitors.
point to a role for inflammation in restenosis. Accord- account that atherosclerosis in animals is induced by
stronger stimuli than those present in human disease,ingly, it has been shown that patients who develop unsta-
such as vessel injury and/or experimental diets that raiseble angina following directional coronary atherectomy
lipid levels far greater than that seen in humans. Hence,have more macrophages and T lymphocytes in the ath-
the use of high doses of statins in these studies seems toerosclerotic lesions than those who have only stable an-
be proportional to the aggressive disease induced. Thegina or stay asymptomatic [135]. Thus, although most
same problem arises when interpreting in vitro studies.promising therapies, such as local delivery of antiprolif-
The concentrations used to demonstrate the biologicalerative drugs, are now introduced to control post-stent
effects of statins in cell culture, especially with regardrestenosis [136], statins may provide a positive effect in
to inhibition of Rho gerenylgeranylation, appear to bethis situation due to their anti-inflammatory effects.
much higher than those prescribed clinically. However,
it is possible that concentrations of statins needed to
LIMITATIONS TO THE INTERPRETATION OF affect activated cells are lower than those needed to
THE LITERATURE affect normal cells. In addition, one may assume that in
Combining clinical with experimental data, as in this vivo, relatively low, but sustained blood levels of statins
review, provides a comprehensive way to explain the could exert a similar effect to that seen in vitro with
benefit and mechanisms of action of any drug. However, higher concentrations and short incubation times.
the value and limitations of every source of knowledge Another common question when analyzing drug ac-
must be clearly pointed out. One of the most common tions is whether there is a “class effect” and all the mem-
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